Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Group (NASDAQ: REPL), a clinical stage biotechnology company focused on oncolytic immunotherapies, has granted inducement equity awards to 10 newly hired non-executive employees. The compensation package includes:
- 11,085 non-qualified stock options with an exercise price of $12.29 per share (closing price on March 5, 2025)
- 22,225 restricted stock units
The stock options have a 10-year term with a 4-year vesting schedule: 25% vesting after one year, followed by monthly installments over three years. The restricted stock units vest in four approximately equal annual installments starting February 15, 2026. These inducement awards, approved under Nasdaq Listing Rule 5635(c)(4), align with the terms of the Company's 2018 Equity Incentive Plan.
Replimune Group (NASDAQ: REPL), un'azienda biotecnologica in fase clinica focalizzata sulle immunoterapie oncolitiche, ha concesso premi azionari di indennità a 10 nuovi dipendenti non esecutivi. Il pacchetto retributivo include:
- 11.085 opzioni su azioni non qualificate con un prezzo di esercizio di $12,29 per azione (prezzo di chiusura del 5 marzo 2025)
- 22.225 unità azionarie vincolate
Le opzioni su azioni hanno una durata di 10 anni con un programma di maturazione di 4 anni: il 25% matura dopo un anno, seguito da rate mensili per tre anni. Le unità azionarie vincolate maturano in quattro rate annuali approssimativamente uguali a partire dal 15 febbraio 2026. Questi premi di indennità, approvati secondo la Regola di Quotazione Nasdaq 5635(c)(4), sono in linea con i termini del Piano di Incentivi Azionari del 2018 dell'azienda.
Replimune Group (NASDAQ: REPL), una empresa biotecnológica en etapa clínica centrada en inmunoterapias oncolíticas, ha otorgado premios de acciones de incentivo a 10 nuevos empleados no ejecutivos. El paquete de compensación incluye:
- 11,085 opciones sobre acciones no calificadas con un precio de ejercicio de $12.29 por acción (precio de cierre del 5 de marzo de 2025)
- 22,225 unidades de acciones restringidas
Las opciones sobre acciones tienen un plazo de 10 años con un calendario de adquisición de 4 años: el 25% se adquiere después de un año, seguido de cuotas mensuales durante tres años. Las unidades de acciones restringidas se adquieren en cuatro cuotas anuales aproximadamente iguales a partir del 15 de febrero de 2026. Estos premios de incentivo, aprobados bajo la Regla de Cotización de Nasdaq 5635(c)(4), están alineados con los términos del Plan de Incentivos de Capital de 2018 de la Compañía.
Replimune Group (NASDAQ: REPL), 종양 면역 요법에 중점을 둔 임상 단계 생명공학 회사가 10명의 새로 고용된 비상 executive 직원에게 유인 주식 보상을 부여했습니다. 보상 패키지에는 다음이 포함됩니다:
- 주당 $12.29의 행사가로 11,085개의 비자격 주식 옵션
- 22,225개의 제한된 주식 단위
주식 옵션은 10년의 기간을 가지며 4년의 베스팅 일정이 있습니다: 1년 후 25%가 베스팅되며, 이후 3년 동안 월별 할부로 지급됩니다. 제한된 주식 단위는 2026년 2월 15일부터 시작하여 대략 동일한 4개의 연간 할부로 베스팅됩니다. 이러한 유인 보상은 Nasdaq 상장 규칙 5635(c)(4) 아래 승인되었으며, 회사의 2018년 주식 인센티브 계획의 조건과 일치합니다.
Replimune Group (NASDAQ: REPL), une entreprise de biotechnologie en phase clinique spécialisée dans les immunothérapies oncolytiques, a accordé des récompenses en actions d'incitation à 10 nouveaux employés non exécutifs. Le package de rémunération comprend :
- 11 085 options d'achat d'actions non qualifiées avec un prix d'exercice de $12,29 par action (prix de clôture au 5 mars 2025)
- 22 225 unités d'actions restreintes
Les options d'achat d'actions ont une durée de 10 ans avec un calendrier d'acquisition de 4 ans : 25 % deviennent acquises après un an, suivi de versements mensuels pendant trois ans. Les unités d'actions restreintes deviennent acquises en quatre versements annuels approximativement égaux à partir du 15 février 2026. Ces récompenses d'incitation, approuvées selon la règle de cotation Nasdaq 5635(c)(4), sont conformes aux termes du Plan d'Incitation en Actions de l'entreprise de 2018.
Replimune Group (NASDAQ: REPL), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf onkolytische Immuntherapien konzentriert, hat 10 neu eingestellten nicht-executive Mitarbeitern Anreizaktienoptionen gewährt. Das Vergütungspaket umfasst:
- 11.085 nicht qualifizierte Aktienoptionen mit einem Ausübungspreis von $12,29 pro Aktie (Schlusskurs am 5. März 2025)
- 22.225 eingeschränkte Aktieneinheiten
Die Aktienoptionen haben eine Laufzeit von 10 Jahren mit einem 4-jährigen Vesting-Plan: 25% vesten nach einem Jahr, gefolgt von monatlichen Raten über drei Jahre. Die eingeschränkten Aktieneinheiten vesten in vier ungefähr gleichen jährlichen Raten, beginnend am 15. Februar 2026. Diese Anreizvergaben, die gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt wurden, stehen im Einklang mit den Bedingungen des Aktienoptionsplans der Gesellschaft von 2018.
- None.
- None.
WOBURN, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.
The Company granted equity awards to 10 employees as a material inducement to commencing their employment with the Company. The inducement awards consist of non-qualified stock options to purchase an aggregate of 11,085 shares of the Company's common stock and restricted stock units representing an aggregate of 22,225 shares of the Company's common stock. Each option has an exercise price of
The aforementioned inducement awards were approved by the compensation committee of the Company's board of directors in reliance on the employment inducement exception under Nasdaq Listing Rule 5635(c)(4). While the inducement awards were granted outside of the Company’s 2018 Equity Incentive Plan, the awards will have terms and conditions consistent with those set forth under such plan.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
What equity awards did Replimune (REPL) grant to new employees in March 2025?
What is the vesting schedule for REPL's March 2025 stock options?
When do the restricted stock units (RSUs) granted by Replimune in March 2025 vest?
What was the exercise price for Replimune's March 2025 inducement stock options?
